Emergent BioSolutions

Contributing Author

Recent Articles by Emergent BioSolutions

Oct-08	Emergent BioSolutions to Report Third Quarter 2025 Financial Results on October 29, 2025 EBS GlobeNewswire
Sep-24	Emergent BioSolutions Recognizes Several Important Observances to Help Save Lives from Opioid Poisoning and Encourages Preparedness with Life-Saving Naloxone EBS GlobeNewswire
Sep-19	Emergent BioSolutions Secures $29 Million in MCM Product Orders from International Government Partner EBS GlobeNewswire
Sep-15	Emergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension TEMBEXA (brincidofovir), a Smallpox Antiviral, and Strengthens Overall U.S. Supply Chain EBS GlobeNewswire
Sep-09	Emergent BioSolutions Receives New Contract Modification for ACAM2000, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness EBS GlobeNewswire
Sep-02	Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use EBS GlobeNewswire
Aug-29	Emergent BioSolutions Underscores Continued Support of Increasing Naloxone Awareness Through Public Education Campaign on International Overdose Awareness Day EBS GlobeNewswire
Aug-27	Emergent BioSolutions to Participate in Upcoming Investor Conferences EBS GlobeNewswire
Aug-21	Emergent BioSolutions Supports Voices for Awareness and Facing Fentanyl Now on August 21, 2025 for National Fentanyl Prevention and Awareness Day EBS GlobeNewswire
Aug-06	Emergent BioSolutions Reports Second Quarter 2025 Financial Results EBS GlobeNewswire
Jul-28	New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox EBS GlobeNewswire
Jul-28	Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. House of Representatives EBS GlobeNewswire
Jul-15	Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025 EBS GlobeNewswire
Jul-08	Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016 [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts EBS GlobeNewswire
Jul-02	Emergent BioSolutions Expands NARCANDirect to Offer KLOXXADO (naloxone HCl) Nasal Spray 8 mg and Convenience Kits Amid Changes in Overdose Death Rate EBS GlobeNewswire
Jun-23	Emergent BioSolutions Secures $62.4 Million Contract Modification for BAT [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine)] to Bolster U.S. Biodefense Supply EBS GlobeNewswire
Jun-20	Emergent BioSolutions Announces Addition to Russell 3000 Index EBS GlobeNewswire
Jun-05	Emergent BioSolutions Supports Victoria's Voice Foundation's National Naloxone Awareness Day Efforts on June 6 to Encourage Americans to Be Prepared for Opioid Emergencies EBS GlobeNewswire
May-14	Emergent BioSolutions to Participate in Upcoming Investor Conferences EBS GlobeNewswire
May-07	Emergent BioSolutions Reports First Quarter 2025 Financial Results EBS GlobeNewswire
May-01	Emergent BioSolutions Reinforces Commitment to Opioid Emergency Preparedness Efforts in Canada Through Multi-Year Contract with Ontario Ministry of Health EBS GlobeNewswire

Emergent BioSolutions

Recent Articles by Emergent BioSolutions

Upgrade your FINVIZ experience